Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirum Pharmaceuticals Inc (NQ: MIRM ) 40.72 UNCHANGED Streaming Delayed Price Updated: 4:15 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mirum Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 January 04, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index December 15, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021 December 13, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting December 06, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Expert Ratings For Mirum Pharmaceuticals September 30, 2021 Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst rat... Via Benzinga The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO August 05, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... Via Benzinga Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences November 22, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher November 17, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update November 15, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome November 15, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Earnings Scheduled For November 15, 2021 November 15, 2021 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to... Via Benzinga The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More November 14, 2021 Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... Via Benzinga Exposures Product Safety Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021 November 08, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021 November 01, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome November 01, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire 10 Biggest Price Target Changes For Thursday September 30, 2021 Jefferies raised Perrigo Company plc (NYSE:PRGO) pr... Via Benzinga FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma September 29, 2021 The FDA has approved Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus in patients with Alagille syndrome (... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Wednesday's After-Market Session September 29, 2021 Gainers Regencell Bioscience (NASDAQ:RGC)... Via Benzinga U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older September 29, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum, Takeda Ink Maralixibat Licensing Pact In Japan September 21, 2021 Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for... Via Benzinga The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug September 29, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... Via Benzinga Exposures Product Safety Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan September 21, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire What 5 Analyst Ratings Have To Say About Mirum Pharmaceuticals September 20, 2021 Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed ... Via Benzinga Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison September 13, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 10, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Participate in September Investor Conferences September 02, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates August 31, 2021 August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... Via Benzinga Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors August 19, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 10, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update August 05, 2021 From Mirum Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
